AXL and non-small cell lung carcinoma: Osimertinib (rather than gefitinib or erlotinib), anti-AXL monoclonal antibodies, and targeted autophagy may improve the efficacy of EGFR-targeting therapy for LDOC1(−) EGFRM NSCLC.